Avicanna's subsidiary obtains GPP certification and authorization by INVIMA for the compounding and sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia – Yahoo Finance

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

  • Authorized cannabinoid products will be available to the medical community and patients in early Q4 2020 including Avicanna’s advanced oral, sublingual, and topical formulations branded and sold as RHO Phyto™ in Canada and other markets.
  • This is the first ever compound pharmacy in Colombia authorized to specialize only in the production of cannabinoid formulations and the first authorized to offer topicals.
  • This is the final step in Avicanna’s fully integrated seed to patient business model in Colombia, which includes cultivation, extraction and manufacturing of pharmaceutical products for the emerging medical market with the 50 million people.

    TORONTO, Sept. 14, 2020 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that through its wholly owned subsidiary Avicanna LATAM S.A.S. (“Avicanna LATAM”), the Company’s pharmacy in Bogota has been certified with Good Preparation Practices (“GPP”) and authorized by the National Institute for Drug and Food Surveillance (“INVIMA”) for the sale of compounded pharmaceutical products to service medical prescriptions of individual patients in Colombia.

    TSX : AVCN (CNW Group/Avicanna Inc.)More

    “We are thrilled to be able to offer our pharmaceutical preparations to the Colombian medical and patient communities. While the medical cannabis market in Colombia is still in its infancy, we are committed to educating both physicians and the medical community of the benefits and potential risks of cannabinoid-based medicine for their patients. We are leveraging years of learning and extensive research and development allowing us to provide the Colombian population with standardized and advanced medical solutions.” Aras Azadian CEO,

    Read More Here...

    Share on facebook
    Share on twitter
    Share on reddit
    Share on pinterest
    Share on email

  • Leave a Comment

    Your email address will not be published. Required fields are marked *

    Scroll to Top